United States Patent 10,258,619: Conjoint Glutaminase Inhibition With Immuno-Oncology in Melanoma and Colon Cancer

US 10,258,619 is drafted as a treatment-method patent centered on (i) conjoint administration of a glutaminase inhibitor defined by a broad, substituent-rich Formula (I)/(Ia)/(II) and (ii) an immuno-oncology therapeutic agent selected from a wide class of immune checkpoint and immunomodulatory drugs, with explicit focus on melanoma or colon cancer. The core novelty claim is functional: reduced tumor viability via cancer-specific combination effects (additive or synergistic), while the breadth is carried by an unusually wide chemical Markush for the glutaminase inhibitor and an unusually broad enumerated class for immuno-oncology agents.

What exactly does claim 1 cover?

Claim 1 is a method of treating cancer by conjointly administering:

A glutaminase inhibitor that is a compound of Formula (I) (or pharmaceutically acceptable salt), where:
- L is one of: CH2SCH2, CH2CH2, CH2CH2CH2, CH2, CH2S, SCH2, CH2NHCH2, CH=CH, or another depicted thioketone-like substituent option (with additional substitution rules).
- X is independently S, O, or CH=CH (with alkyl substitutions allowed on the CH units).
- Y is H or CH2O(CO)R7 (with R7 varying across H and many substituent categories).
- Z is H or R3(CO).
- R1 and R2 are independently H, alkyl, alkoxy, or hydroxy.
- R3 is heavily generalized across substituted/unsubstituted alkyl and multiple heteroaryl/aryl/alkoxy classes, plus carbocycles/heterocycles and related “at least two not H” constraints.
An immuno-oncology therapeutic agent (as later claims restrict by definition, but claim 1 itself is open-ended).
The target cancer is melanoma or colon cancer.
Therapeutic effect is implied via the combination framing in dependent claims, including potential improved efficacy over monotherapy and additive or synergistic effects.

Dependent claims 2–4 add effect-based differentiation:

Claim 2: conjoint administration improves efficacy vs each agent alone.
Claim 3: conjoint administration gives an additive effect.
Claim 4: conjoint administration gives a synergistic effect.

Claim 5 limits the immuno-oncology agent to inhibitors or targets that include:

arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.

Claim 6 enumerates a large set of named immuno-oncology agents (including PD-1/PD-L1 drugs and antibodies and other immunotherapies).

How broad is the glutaminase-inhibitor chemical space (and what does that mean legally)?

The glutaminase inhibitor portion is the main expansion lever. Claim 1’s Formula (I) uses multiple independent variables (L, X, Y, Z, R1–R3, and substituent-rich R8–R10) with:

multiple alternative core linkers (L),
heteroatom substitutions (X),
prodrug-capable O-acyl/ester motifs (Y includes CH2O(CO)R7, and hydroxyl groups can be acylated),
flexible acyl/alkoxy/hydroxyl/aryl/heteroaryl substitution possibilities, and
a structural constraint that at least two of R8, R9, and R10 are not H (which is a tethered stereochemical/structural requirement, but still leaves substantial freedom).

Dependent claims then carve the chemical set into more specific sub-formulas:

Claim 7 narrows L to CH2CH2.
Claim 8 narrows Y to H.
Claim 9 restricts X to S or CH=CH.
Claim 10 narrows Z to R3(CO).
Claim 12 sets R1 and R2 to H.
Claim 13 narrows R3 to arylalkyl/heteroarylalkyl/cycloalkyl/heterocycloalkyl.
Claim 14 provides additional substructure detail and adds R11 and constraints on R12/R13 (both not H).

Claim 14’s added “R11/R12/R13/R14” layering increases specificity, but still stays inside a Markush framework with broad allowed substituent classes and ring-forming possibilities.

Table: claim structure map

Claim element	What it covers	Practical breadth
Cancer type	Melanoma or colon cancer	Moderate (only 2 indications)
Administration format	“Conjointly administering” glutaminase inhibitor + immuno-oncology agent	Potentially broad in scheduling (simultaneous or coordinated dosing depending on prosecution/interpretation)
Glutaminase inhibitor	Formula (I), plus salts; later sub-formulas (Ia), (II)	Very broad chemically due to many independent variables
Immuno-oncology agent	Open in claim 1; then restricted by dependent claims (PD-1/PD-L1, CTLA-4, etc.) and by long enumerated list in claim 6	Broad due to named drug list and inclusion of multiple immuno targets

What does the patent require for the immuno-oncology partner?

Claim 5 ties the immuno-oncology agent to specific immunosuppressive pathways (arginase, CTLA-4, IDO, PD-1/PD-L1). Claim 6 then expands as an enumerated list including:

PD-1 inhibitors: lambrolizumab (likely pembrolizumab misspelling in the text), nivolumab, pidilizumab, etc.
PD-L1 inhibitors: durvalumab, atezolizumab variants like MPDL3280A (atezolizumab), and similar.
CTLA-4: ipilimumab and tremelimumab (CTLA-4 variants depending on drug).
Other immunomodulators: abagovomab, adecatumumab, afutuzumab, alemtuzumab, anatumomab mafenatox, ofatumumab, etc.
IDO inhibitors: epacadostat, indoximod (IDO pathway).
Arginase/other metabolic immunoregulators: samalizumab (anti-CD11? in older naming), and others.

Legally, the combination coverage becomes defendant-friendly: once the glutaminase inhibitor falls within Formula (I)/(Ia)/(II), a wide range of immuno-oncology antibodies can be used to land inside the claim via dependent claim 6.

How does the landscape look in terms of “combination obviousness” and overlap?

Even without reviewing the specification text, the combination claim structure resembles a common litigation pattern:

A first pillar: targeting glutamine metabolism (glutaminase inhibition) in tumors.
A second pillar: modulating immune checkpoints (PD-1/PD-L1, CTLA-4) and other immune escape pathways.
A third pillar: alleging that combining metabolic restriction with immune checkpoint modulation yields improved or synergistic outcomes.

This structure invites a typical invalidity attack:

Anticipation: If prior art discloses conjoint administration of (a) glutaminase inhibitors and (b) the same immuno-oncology classes (especially PD-1/PD-L1 or CTLA-4 antibodies) in the same cancer types (melanoma/colon) with materially overlapping compositions.
Obviousness: If each component is known and the rationale to combine them is already in the record (e.g., glutaminase inhibition enhances T-cell function, alters myeloid populations, reduces immunosuppression, and checkpoint therapy benefits from a pro-immune tumor microenvironment).
Written description / enablement: Because the chemical Markush is broad, challengers often argue that the application does not enable the entire genus or does not provide representative examples across the genus at sufficient level.

The fact that claims explicitly state additive and synergistic effects helps the patentee in infringement narratives but does not immunize against obviousness. Courts treat “synergy” as a factual issue tethered to the evidentiary record; if prior art suggests predictable combination effects, the synergy label can be attacked as conclusory unless backed by comparative data.

Key claim-dependent narrowings that matter for enforcement

These dependent claims are the strongest “pivot points” for both infringement mapping and design-around:

Table: enforceable pivot points

Dependent claim	What it narrows	Why it matters
Claim 7	L = CH2CH2	Narrows the linker variation; useful if accused compound has different linker
Claim 8	Y = H	Excludes prodrug/ester forms where Y is CH2O(CO)R7
Claim 9	X = S or CH=CH	Narrows heteroatom/unsaturation options
Claim 10	Z = R3(CO)	Requires specific carbonyl substitution on the Z-linked group
Claim 12	R1 = H and R2 = H	Reduces substitution diversity in core groups
Claim 13	R3 restricted to arylalkyl / heteroarylalkyl / cycloalkyl / heterocycloalkyl	Strong for avoiding specific scaffolds
Claim 16 / 17	melanoma or colon cancer	Keeps the claim within two clinical indications
Claim 18	allows additional chemotherapeutic agents	Defenses combination regimens from “not exactly your two-agent protocol” attacks
Claim 19 / 20	explicitly pairs formula (II) glutaminase inhibitors with anti-PD-L1 / anti-PD-1	Creates direct infringement pathways if formula (II) is used with the named checkpoint antibodies

What are the risk zones for a company planning a PD-1/PD-L1 + glutaminase program?

1) If the glutaminase inhibitor is within Formula (I)/(Ia)/(II)

Then the combination choice matters less because claim 6 provides a long immuno-oncology list. If the immune agent is PD-1/PD-L1, CTLA-4, IDO, or arginase related, defendants will still fight for claim construction and chemical scope, but the “second ingredient” is easy to satisfy.

2) If the inhibitor uses ester/prodrug motifs governed by Y and acylated hydroxyl rules

Claim 1 explicitly allows acylation of free hydroxyl groups and includes Y = CH2O(CO)R7. That undermines a common design-around where developers convert to different prodrug esters. To avoid literal infringement, the molecule likely needs to step outside one of the structural variable constraints (L/X/Y/Z/R1/R2/R3/R8–R10).

3) “Conjointly administering” interpretation

Because claim language is method-based and does not define sequence, timing, or formulation separation, enforcement typically argues a broad meaning consistent with coordinated treatment. This becomes important if the competitor uses separate schedules, different administration routes, or alternating cycles.

How does the patent’s claim approach compare with typical metabolic-immuno combination filings?

US 10,258,619 is closer to a “platform genus + broad immuno-oncology partner list” than to a narrow “one specific compound + one specific antibody + one specific dose” patent. That drafting strategy:

expands the number of potential infringers (anyone using a covered glutaminase inhibitor with broad checkpoint immunotherapy in melanoma/colon),
increases leverage in settlement talks (more product variants can be asserted),
raises validity risk by increasing chemical/genus breadth (and thus enabling/description challenges).

Where are the most likely invalidity or non-infringement pressure points?

A) Chemical structure scope and prosecution history estoppel

With Markush claims as broad as this one, challengers often litigate:

which specific structural elements are truly required (and which are permissive),
whether a competitor’s compound differs in one of L/X/Y/Z or the “at least two not H” region, and
whether salts or tautomeric/prodrug forms count.

B) “Therapeutically treating cancer… wherein the cancer is melanoma or colon cancer”

If the accused therapy is used clinically in a different cancer type, the claim does not cover it under its face value. If the accused label or trial includes multiple indications, the patentee will try to tie the claimed method to off-label use in melanoma/colon. Defendants may challenge evidence of actual treatment in the claimed indications.

C) Synergy/additivity claims

Claims 2–4 encode “improved efficacy relative to individual administration” and “additive/synergistic effect.” Those are susceptible to:

prior art that teaches improved efficacy of metabolic therapy plus checkpoint blockade,
arguments that synergy is not demonstrated with rigorous design and proper controls,
arguments that “synergistic” is not a structural limitation and depends on data.

What is the practical “patent landscape” conclusion from the claim set alone?

Within the four corners of the claims provided, US 10,258,619 creates a strong assertion surface in a specific niche:

Cancer: melanoma and colon cancer.
Therapeutic class: glutaminase inhibition.
Combination partner: broad immuno-oncology agents with explicit inclusion of PD-1/PD-L1 and other immune pathway modulators.
Chemical breadth: very large genus under Formula (I)/(Ia)/(II), with many substitution degrees of freedom.

The landscape pressure will therefore cluster around:

programs using glutaminase inhibitors in melanoma/colon with checkpoint antibodies, and
programs that attempt to reposition metabolic inhibitors as immune modulators.

The patent’s drafting also implies that non-infringement efforts should focus primarily on chemical exclusion (stepping outside Formula (I)/(Ia)/(II)) rather than switching immune partners, because claim 6 already covers many antibodies and immune drugs.

Key Takeaways

US 10,258,619 claims a method for melanoma or colon cancer using conjoint administration of a glutaminase inhibitor defined by broad Formula (I)/(Ia)/(II) with a wide range of immuno-oncology agents, including PD-1/PD-L1 and CTLA-4/IDO/arginase-related therapies.
The strongest enforcement lever is the combination plus the genus-level Markush for the glutaminase inhibitor; the strongest defensive lever is likely chemical non-coverage (L/X/Y/Z and R-group constraints).
The “additive/synergistic” language strengthens infringement narratives but does not prevent standard invalidity routes based on known components, known combination rationale, and genus-enablement arguments.
Dependent claims 19–20 create direct, easy-to-map combination assertions where the immuno partner is specifically anti-PD-L1 or anti-PD-1 and the inhibitor is in Formula (II).

FAQs

Is claim 1 limited to PD-1/PD-L1 therapies?
No. Claim 1 is open on the immuno-oncology therapeutic agent; PD-1/PD-L1 is covered through dependent claims (e.g., claim 5 and claim 19/20) and through the enumerated list in claim 6.
Does the patent cover other cancers beyond melanoma and colon?
The claim language provided limits cancer type in claim 1 to melanoma or colon cancer. Coverage beyond those would require additional claims not provided here.
Is “synergistic effect” a structural requirement?
No. It is an outcome statement in dependent claims (2–4). It is typically treated as a factual/functional property rather than a chemical or administration structural limitation.
Which part of the claim set is most important for a design-around strategy?
The glutaminase inhibitor structure under Formula (I)/(Ia)/(II), especially the variable definitions for L, X, Y, Z, R1/R2, R3, and the constrained substituent pattern involving R8/R9/R10.
Can a regimen include additional chemotherapy?
Claim 18 says yes: the method can include one or more additional chemotherapeutic agents while still meeting the claimed “conjointly administering” requirement.

References

[1] United States Patent US 10,258,619.

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	⤷ Start Trial	2036-10-04
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	⤷ Start Trial	2036-10-04
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	⤷ Start Trial	2036-10-04
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	October 12, 2004	⤷ Start Trial	2036-10-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017062354	⤷ Start Trial
United States of America	2021361649	⤷ Start Trial
United States of America	2019231776	⤷ Start Trial
United States of America	2017095473	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 10,258,619

Summary for Patent: 10,258,619